2SPD-025 Acalabrutinib + obinutuzumab versus ibrutinib + obinutuzumab as first line in chronic lymphocytic leukemia | European Journal of Hospital Pharmacy

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via EAHP

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens
Log in via EAHP

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

Section 2: Selection, procurement and distribution

2SPD-025 Acalabrutinib + obinutuzumab versus ibrutinib + obinutuzumab as first line in chronic lymphocytic leukemia

Free

Online download statistics by month:

Online download statistics by month: March 2022 to September 2024

	Abstract	Full	Pdf
Mar 2022	37	0	4
Apr 2022	32	0	4
May 2022	18	0	4
Jun 2022	19	0	3
Jul 2022	37	0	6
Aug 2022	14	0	5
Sep 2022	17	0	4
Oct 2022	14	0	0
Nov 2022	11	0	1
Dec 2022	14	0	2
Jan 2023	14	0	0
Feb 2023	6	0	3
Mar 2023	14	0	1
Apr 2023	10	0	2
Jun 2023	0	0	1
Jul 2023	6	0	2
Aug 2023	0	0	1
Sep 2023	7	0	0
Oct 2023	2	0	1
Nov 2023	15	0	3
Dec 2023	8	0	5
Jan 2024	6	0	1
Feb 2024	4	0	2
Mar 2024	24	0	1
Apr 2024	13	0	3
May 2024	5	0	1
Jun 2024	4	0	1
Jul 2024	3	0	4
Aug 2024	9	0	2
Sep 2024	1	0	0
Total	364	0	67